Micafungin Use in the Treatment of Pediatric Fungal Infections
Micafungin Use in the Treatment of Pediatric Fungal Infections
Use of micafungin is contraindicated in patients with a previous history of a hypersensitivity reaction to it or any other echinocandin. Rare, but serious hypersensitivity reactions, including anaphylaxis and anaphylactoid reactions, have been reported with micafungin administration. Isolated cases of acute intravascular hemolysis and hemolytic anemia have been reported in patients receiving micafungin. Approximately 4–10% of children in clinical trials have developed decreased urine output or elevated serum transaminases and hyperbilirubinemia during micafungin administration. In these cases, continued use of micafungin should be evaluated based on the relative benefit of treatment. If therapy is continued, appropriate monitoring tests should be continued throughout treatment.
Contraindications and Warnings
Use of micafungin is contraindicated in patients with a previous history of a hypersensitivity reaction to it or any other echinocandin. Rare, but serious hypersensitivity reactions, including anaphylaxis and anaphylactoid reactions, have been reported with micafungin administration. Isolated cases of acute intravascular hemolysis and hemolytic anemia have been reported in patients receiving micafungin. Approximately 4–10% of children in clinical trials have developed decreased urine output or elevated serum transaminases and hyperbilirubinemia during micafungin administration. In these cases, continued use of micafungin should be evaluated based on the relative benefit of treatment. If therapy is continued, appropriate monitoring tests should be continued throughout treatment.